Senseonics Holdings, Inc. Schedules First Quarter 2025 Earnings Release and Conference Call for May 8, 2025 at 4:30 P.M. Eastern Time

Rhea-AI Summary

Senseonics Holdings, a pioneer in medical technology focusing on implantable continuous glucose monitoring (CGM) systems for diabetes patients, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.

The company will host a conference call at 4:30 PM Eastern Time on the same day to discuss Q1 2025 performance. Investors can participate through multiple channels:

• Conference call: US/Canada: 1-800-343-4136
• International: 1-203-518-9843
• Passcode: SENSQ1
• Webcast: Available on www.senseonics.com under Investor Relations

The webcast will be archived on the company's website for future reference. Participants are advised to dial in 5-10 minutes before the start time.

News Market Reaction

-0.65%

1 alert

-0.65% News Effect

On the day this news was published, SENS declined 0.65%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

GERMANTOWN, Md., April 29, 2025 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that it plans to release its first quarter 2025 financial results after market close on Thursday, May 8, 2025.

Management will hold a conference call to review the Company’s first quarter 2025 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com by navigating to “Investor Relations,” and then “Events & Publications,” and will be archived there for future reference. To listen to the conference call, please dial 1-800-343-4136 (US/Canada) or 1-203-518-9843 (International), passcode SENSQ1, approximately ten to five minutes prior to start time.

About Senseonics
Senseonics Holdings, Inc. ("Senseonics") is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems Eversense^® 365 and Eversense^® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.

Senseonics Investor Contact

Jeremy Feffer
LifeSci Advisors
investors@senseonics.com

FAQ

When will Senseonics (SENS) release Q1 2025 earnings?

Senseonics (SENS) will release its Q1 2025 earnings after market close on Thursday, May 8, 2025.

How can I listen to Senseonics (SENS) Q1 2025 earnings call?

You can listen to the earnings call by dialing 1-800-343-4136 (US/Canada) or 1-203-518-9843 (International) with passcode SENSQ1, or join the webcast through Senseonics' investor relations website.

What time is Senseonics (SENS) Q1 2025 earnings conference call?

The earnings conference call is scheduled for 4:30 p.m. Eastern Time on May 8, 2025.

Where can I find Senseonics (SENS) Q1 2025 earnings webcast?

The earnings webcast will be available on www.senseonics.com under 'Investor Relations' and 'Events & Publications' sections, where it will also be archived for future reference.

What does Senseonics (SENS) company do?

Senseonics is a medical technology company that develops and manufactures long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes.